查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828045

2025年全球循環性腫瘤細胞市場報告

Circulating Tumor Cells Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，循環性腫瘤細胞市場規模迅速擴張，從2024年的119億美元成長到2025年的132.7億美元，複合年成長率為11.5%。預測期內的成長可歸因於多種因素，例如癌症的發生率和盛行率、其在癌症分期中的臨床效用、液態切片的興起、患者對微創檢測的需求、監管部門對液態切片的支持以及對早期癌症檢測的重視。

預計未來幾年循環性腫瘤細胞市場將快速成長，到2029年將達到213.8億美元，年複合成長率（CAGR）為12.7%。預測期內的成長可歸因於照護現場CTC檢測、微射流的普及、對罕見癌症類型的關注、CTC檢測的標準化、基於CTC的臨床檢測的擴展、經濟成長以及新興市場的成長。預測期內的主要趨勢包括CTC分離技術的創新、政府對CTC研究的資助、CTC檢測技術的進步、用於癌症監測的液態切片、與單細胞分析的整合以及與人工智慧 (AI) 的技術融合。

循環性腫瘤細胞(CTC) 是從原發性腫瘤脫落並進入血液的固體癌細胞，含有寶貴的癌症診斷和預後資訊。

我們與循環性腫瘤細胞相關的主要產品包括套件和試劑、採集管以及設備或系統。套件和試劑包含一整套耗材，包括血液檢體分離器、專有微流體捕獲晶片以及CTC富集和免疫染色試劑。這些產品用於採集人體各種檢體，包括血液、骨髓和其他體液。這些產品利用各種技術進行液態切片富集、檢測和分析，以促進臨床檢測、液態生物檢體和研究應用。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供循環性腫瘤細胞市場統計數據，包括全球市場規模、區域佔有率、競爭對手的市場佔有率、詳細的循環性腫瘤細胞循環性腫瘤細胞細胞細分市場、市場趨勢和商業機會，以及您在循環循環性腫瘤細胞行業循環性腫瘤細胞。本循環性腫瘤細胞市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年12.7%的預測成長率，較我們先前對該市場的預測略有下降0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。這可能會透過對來自以色列和日本等關鍵地區的微流體捕獲晶片和上皮細胞黏附分子抗體徵收關稅直接影響美國，從而導致轉移性癌症的檢測延遲和液態切片成本的上升。由於互惠關稅以及貿易緊張局勢和限制措施加劇對全球經濟和貿易的負面影響，這種影響也將更加廣泛地顯現。

預計未來癌症發生率的上升將推動循環性腫瘤細胞市場的成長。癌症是一種以某些體細胞不受控制地增殖為特徵的疾病，這些細胞會轉移到身體的其他部位。循環性腫瘤細胞用於癌症的早期檢測和診斷，癌症患者的增加正在促進循環性腫瘤細胞市場的擴張。例如，美國志願組織《美國癌症研究雜誌》預測，到2023年1月，美國將有1,958,310例新發癌症病例和609,820例癌症相關死亡病例。因此，癌症發生率的上升正在刺激循環性腫瘤細胞市場的成長。

循環性腫瘤細胞分析在臨床試驗中的日益普及也可能是市場成長的主要驅動力。臨床試驗對於評估新治療方法的安全性和有效性至關重要，而循環性腫瘤細胞(CTC) 分析的整合則使其受益匪淺。這種整合提高了評估療效的能力，實現了早期檢測和監測，允許根據特定患者情況量身定做干涉措施，並總體上提高了臨床終點的效率和檢驗。截至 2023 年 5 月，ClinicalTrials.gov 報告稱，已註冊 452,604 項臨床試驗，其中 64,838 項正在積極尋找參與者。臨床試驗數量的激增比 2021 年註冊的 365,000 項試驗增加，證實了循環性腫瘤細胞分析在研究中的應用日益廣泛。因此，CTC 分析在臨床試驗中的日益普及是推動循環性腫瘤細胞市場發展的主要因素。

產品創新是推動循環性腫瘤細胞市場發展的關鍵趨勢。該領域的主要企業正專注於開發創新產品，以鞏固其市場地位。例如，2024年6月，美國醫學實驗室Bio-Rad Laboratories, Inc.推出了Celselect Slides 2.0。該產品旨在透過改進對稀有細胞或CTC（循環性腫瘤細胞）的捕獲，提高臨床和研究應用中細胞分析的準確性和效率。

循環性腫瘤細胞市場包括臨床樣本、KRT7、PSMA 陽性細胞和 TTF-1 陽性細胞的銷售。該市場的價值為“出廠價”，即商品製造商或創造者出售給其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接出售給最終客戶的價值。該市場中的商品價值還包括商品創造者出售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球循環性腫瘤細胞：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球循環性腫瘤細胞市場：成長率分析
  • 全球循環性腫瘤細胞市場表現：規模與成長，2019-2024
  • 全球循環性腫瘤細胞市場預測：規模與成長，2024-2029，2034
  • 全球循環性腫瘤細胞：總潛在市場（TAM）

第6章 市場細分

  • 全球循環性腫瘤細胞市場（依產品、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 套件和試劑
  • 採血管
  • 設備或系統
  • 全球循環性腫瘤細胞市場（依技術、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • CTC富集
  • CTC檢測
  • CTC分析
  • 全球循環性腫瘤細胞市場樣本、表現及預測（2019-2024、2024-2029、2034）
  • 血
  • 骨髓
  • 其他
  • 全球循環性腫瘤細胞市場的應用、表現與預測，2019-2024年、2024-2029年、2034年
  • 切片檢查或液態生物檢體
  • 研究
  • 全球循環性腫瘤細胞市場：套件和試劑細分、類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 細胞富集試劑套件
  • 檢測試劑套件
  • 核酸分離試劑套件
  • 全球循環性腫瘤細胞市場：採血管細分，按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 標準採血管
  • 專用採血管
  • 全球循環性腫瘤細胞市場：設備或系統細分，按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 微流體設備
  • 自動細胞捕獲系統
  • 影像系統

第7章 區域和國家分析

  • 全球循環性腫瘤細胞市場：2019-2024 年、2024-2029 年和 2034 年區域表現和預測
  • 全球循環性腫瘤細胞市場：國家、績效及預測（2019-2024、2024-2029、2034）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 循環性腫瘤細胞市場：競爭格局
  • 循環性腫瘤細胞市場：公司簡介
    • Precision Medicine Group LLC
    • Bio-Techne Corporation
    • BIOCEPT Inc.
    • Creativ MicroTech Inc.
    • Fluxion Biosciences Inc.

第31章：其他領先和創新企業

  • Ikonisys Inc.
  • Qiagen NV
  • ScreenCell SAS
  • STEMCELL Technologies Inc.
  • Sysmex Corporation
  • Aviva Biosciences Corporation
  • LungLife AI Inc.
  • Miltenyi BIoTec GmbH
  • Menarini Silicon Biosystems SpA
  • Canopus Bioscience Ltd.
  • IVDiagnostics Inc.
  • BioFluidica Inc.
  • Biolidics Limited
  • Rarecells Diagnostics SAS
  • LineaRx Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第35章：市場潛力大的國家與策略

  • 2029年循環性腫瘤細胞市場：提供新機會的國家
  • 2029年循環性腫瘤細胞市場：細分市場帶來新機會
  • 循環性腫瘤細胞市場2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r23254u

Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.

The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The circulating tumor cells market research report is one of a series of new reports from The Business Research Company that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The circulating tumor cells market size has grown rapidly in recent years. It will grow from $11.9 billion in 2024 to $13.27 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to cancer incidence and prevalence, clinical utility in cancer staging, emergence of liquid biopsy, patient demand for minimally invasive tests, regulatory support for liquid biopsies, focus on early cancer detection.

The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to point-of-care CTC testing, adoption of microfluidics, focus on rare cancer types, standardization of CTC assays, expansion of CTC-based clinical trials, economic and emerging market growth. Major trends in the forecast period include innovations in CTC isolation techniques, government funding for CTC research, advancements in CTC detection technologies, liquid biopsy for cancer monitoring, integration with single-cell analysis, technological convergence with artificial intelligence (AI).

The forecast of 12.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on microfluidic capture chips and epithelial cell adhesion molecule antibodies, sourced from key regions such as Israel and Japan, which could lead to delays in metastatic cancer detection and higher liquid biopsy expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is expected to drive the growth of the circulating tumor cells market in the future. Cancer is a disease characterized by the uncontrolled growth of certain body cells, which can spread to other areas. Circulating tumor cells are utilized for the early detection and diagnosis of cancer, thereby contributing to the expansion of the circulating tumor cells market as cancer cases rise. For example, in January 2023, the American Cancer Society Journals, a US-based voluntary health organization, projected that 1,958,310 new cancer cases would be diagnosed in the United States, with 609,820 expected cancer-related deaths. Thus, the rising incidence of cancer is fueling the growth of the circulating tumor cells market.

The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.

Product innovations are a significant trend gaining traction in the circulating tumor cells market. Major companies in this sector are concentrating on developing innovative products to bolster their market position. For example, in June 2024, Bio-Rad Laboratories, Inc., a US-based medical laboratory, introduced the Celselect Slides 2.0. This product is designed to improve the capture of rare cells and circulating tumor cells (CTCs), thereby enhancing the accuracy and efficiency of cell analysis for both clinical and research applications.

Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.

In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).

Major companies operating in the circulating tumor cells market include Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd.

North America was the largest region in the circulating tumor cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Circulating Tumor Cells Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on circulating tumor cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for circulating tumor cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The circulating tumor cells market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Kits And Reagents; Blood Collection Tubes; Devices Or Systems
  • 2) By Technology: CTC Enrichment; CTC Detection; CTC Analysis
  • 3) By Specimen: Blood; Bone Marrow; Other Body Fluids
  • 4) By Application: Clinical Or Liquid Biopsy; Research
  • Subsegments:
  • 1) By Kits And Reagents: Cell Enrichment Kits; Detection Kits; Nucleic Acid Isolation Kits
  • 2) By Blood Collection Tubes: Standard Blood Collection Tubes; Specialized Blood Collection Tubes
  • 3) By Devices Or Systems: Microfluidic Devices; Automated Cell Capture Systems; Imaging Systems
  • Companies Mentioned: Precision Medicine Group LLC; Bio-Techne Corporation; BIOCEPT Inc.; Creativ MicroTech Inc.; Fluxion Biosciences Inc.; Ikonisys Inc.; Qiagen N.V.; ScreenCell SAS; STEMCELL Technologies Inc.; Sysmex Corporation; Aviva Biosciences Corporation; LungLife AI Inc.; Miltenyi Biotec GmbH; Menarini Silicon Biosystems S.p.A.; Canopus Bioscience Ltd.; IVDiagnostics Inc.; BioFluidica Inc.; Biolidics Limited; Rarecells Diagnostics SAS; LineaRx Inc.; Thermo Fisher Scientific Inc.; Greiner Bio-One International GmbH; Stanford Research Institute International; Agilent Technologies Inc.; Resolution Bioscience Inc.; Cynvenio Biosystems Inc.; ApoCell Inc.; Clearbridge BioMedics Pte. Ltd.; Celsee Inc.; RareCyte Inc.; On-chip Biotechnologies Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Circulating Tumor Cells Market Characteristics

3. Circulating Tumor Cells Market Trends And Strategies

4. Circulating Tumor Cells Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Circulating Tumor Cells Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Circulating Tumor Cells PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Circulating Tumor Cells Market Growth Rate Analysis
  • 5.4. Global Circulating Tumor Cells Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Circulating Tumor Cells Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Circulating Tumor Cells Total Addressable Market (TAM)

6. Circulating Tumor Cells Market Segmentation

  • 6.1. Global Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kits And Reagents
  • Blood Collection Tubes
  • Devices Or Systems
  • 6.2. Global Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
  • 6.3. Global Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Blood
  • Bone Marrow
  • Other Body Fluids
  • 6.4. Global Circulating Tumor Cells Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Or Liquid Biopsy
  • Research
  • 6.5. Global Circulating Tumor Cells Market, Sub-Segmentation Of Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cell Enrichment Kits
  • Detection Kits
  • Nucleic Acid Isolation Kits
  • 6.6. Global Circulating Tumor Cells Market, Sub-Segmentation Of Blood Collection Tubes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard Blood Collection Tubes
  • Specialized Blood Collection Tubes
  • 6.7. Global Circulating Tumor Cells Market, Sub-Segmentation Of Devices Or Systems, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Microfluidic Devices
  • Automated Cell Capture Systems
  • Imaging Systems

7. Circulating Tumor Cells Market Regional And Country Analysis

  • 7.1. Global Circulating Tumor Cells Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Circulating Tumor Cells Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Circulating Tumor Cells Market

  • 8.1. Asia-Pacific Circulating Tumor Cells Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Circulating Tumor Cells Market

  • 9.1. China Circulating Tumor Cells Market Overview
  • 9.2. China Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Circulating Tumor Cells Market

  • 10.1. India Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Circulating Tumor Cells Market

  • 11.1. Japan Circulating Tumor Cells Market Overview
  • 11.2. Japan Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Circulating Tumor Cells Market

  • 12.1. Australia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Circulating Tumor Cells Market

  • 13.1. Indonesia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Circulating Tumor Cells Market

  • 14.1. South Korea Circulating Tumor Cells Market Overview
  • 14.2. South Korea Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Circulating Tumor Cells Market

  • 15.1. Western Europe Circulating Tumor Cells Market Overview
  • 15.2. Western Europe Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Circulating Tumor Cells Market

  • 16.1. UK Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Circulating Tumor Cells Market

  • 17.1. Germany Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Circulating Tumor Cells Market

  • 18.1. France Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Circulating Tumor Cells Market

  • 19.1. Italy Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Circulating Tumor Cells Market

  • 20.1. Spain Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Circulating Tumor Cells Market

  • 21.1. Eastern Europe Circulating Tumor Cells Market Overview
  • 21.2. Eastern Europe Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Circulating Tumor Cells Market

  • 22.1. Russia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Circulating Tumor Cells Market

  • 23.1. North America Circulating Tumor Cells Market Overview
  • 23.2. North America Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Circulating Tumor Cells Market

  • 24.1. USA Circulating Tumor Cells Market Overview
  • 24.2. USA Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Circulating Tumor Cells Market

  • 25.1. Canada Circulating Tumor Cells Market Overview
  • 25.2. Canada Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Circulating Tumor Cells Market

  • 26.1. South America Circulating Tumor Cells Market Overview
  • 26.2. South America Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Circulating Tumor Cells Market

  • 27.1. Brazil Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Circulating Tumor Cells Market

  • 28.1. Middle East Circulating Tumor Cells Market Overview
  • 28.2. Middle East Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Circulating Tumor Cells Market

  • 29.1. Africa Circulating Tumor Cells Market Overview
  • 29.2. Africa Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Circulating Tumor Cells Market Competitive Landscape And Company Profiles

  • 30.1. Circulating Tumor Cells Market Competitive Landscape
  • 30.2. Circulating Tumor Cells Market Company Profiles
    • 30.2.1. Precision Medicine Group LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. BIOCEPT Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Creativ MicroTech Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Fluxion Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Circulating Tumor Cells Market Other Major And Innovative Companies

  • 31.1. Ikonisys Inc.
  • 31.2. Qiagen N.V.
  • 31.3. ScreenCell SAS
  • 31.4. STEMCELL Technologies Inc.
  • 31.5. Sysmex Corporation
  • 31.6. Aviva Biosciences Corporation
  • 31.7. LungLife AI Inc.
  • 31.8. Miltenyi Biotec GmbH
  • 31.9. Menarini Silicon Biosystems S.p.A.
  • 31.10. Canopus Bioscience Ltd.
  • 31.11. IVDiagnostics Inc.
  • 31.12. BioFluidica Inc.
  • 31.13. Biolidics Limited
  • 31.14. Rarecells Diagnostics SAS
  • 31.15. LineaRx Inc.

32. Global Circulating Tumor Cells Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Circulating Tumor Cells Market

34. Recent Developments In The Circulating Tumor Cells Market

35. Circulating Tumor Cells Market High Potential Countries, Segments and Strategies

  • 35.1 Circulating Tumor Cells Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Circulating Tumor Cells Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Circulating Tumor Cells Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer